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A B S T R A C T
The carcinogenicity (photocarcinogenicity) of sunlight to human skin has been recognized more than a century ago.
Last decades numerous experimental studies show that UV rays damage DNA, cause gene mutations leading to the de-
velopment of malignant tumors such basal cell carcinomas, squamous cell carcinomas and melanomas. The tumors oc-
cur most frequently in fair skinned people, and the mutations typically are found at dipyrimidine sites with C-T or / and
CC-TT tandem double mutations. The authors briefly summarize their investigation of the p53 suppressor gene, and ex-
pose their hypothesis of hTERT involvement in cancerogenesis. Also their underline the importance of UV induced
immunosuppression in photocarcinogenesis. Psoriatic patients are exposed to numerous cancerogens in their treatment.
A better understanding of the mechanisms of photocarcinogenesis could provide new ways in the treatment of skin tu-
mors.
Key words: UV radiation, mutation, telomerase, immunosuppression, psoriasis
Introduction
Malignant skin tumors are the most common tumors
in humans and their incidence is steadily increasing in
our country and worldwide in the last decades1–4. Al-
though a lot of factors may contribute to the develop-
ment of skin tumors such as ionizing radiations, viruses,
arsenic, tar derivates, soot, exposure to products of the
distillation of coal, inflammation, genetic factors, immu-
nologic status and others, the most important environ-
mental factor is the ultraviolet radiation (UVR) from the
sunlight or from artificial sources4–8. In recent years sev-
eral studies have been performed to investigate the role
of UVR in tumorogenesis which demonstrated they can
cause irreversible changes in cell genetic material, initia-
tion, promotion and progression of tumors9–11. So, expo-
sure to UVR induces photocarcinogenesis i.e. the skin
cells acquire genomic alterations that play a key role in
the development of the three most common types of skin
cancer: basal cell carcinomas, squamous cell carcinomas,
which arise from keratinocytes and are collectively na-
med non-melanoma skin cancer (NMSC), and melano-
mas that derive from melanocytes. They share certain
common traits like the rise of incidence with increased
exposure to sunlight, increase with age and different sus-
ceptibility related to pigmentation i.e. mostly develop in
fair skinned people with phototypes I-II after Fitzpatrick
according our and other experience12,13. On the basis of
our investigations and supported by numerous other in
skin malignant tumors as well in others cancers the initi-
ating and leading event is the alteration of the cell ge-
netic material: mutation, amplification or deletion of
some of its genes, like the suppressor gene p53, with al-
teration of their protein products and finally alteration
of signal pathways 14,15.
Immunosuppression induced by UVR has also a role,
and we believe that telomerase has, too. The purpose of
this review is to summarize the current knowledge of the
cellular and molecular events in photocarcinogenesis
even if the heterogeneity of these tumors inevitably have
different pathway.
Effects of UV Radiation on DNA
Although the role of sunlight in the development of
skin cancer was recognized at the end of the XIX cen-
tury16, and the role of UVR in inducing skin cancer was
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demonstrated by Findlay experimentally in albino mice
with a quartz-mercury vapor lamp in 192817, only the in-
troduction of powerful tools for studying the DNA muta-
tions and advances in genetics, molecular biology and im-
munology in the last three decades have improved our
understanding the process of carcinogenesis and particu-
larly photocarcinogenesis.
UVR represents the portion of the electromagnetic
spectrum between visible light and X-rays. According to
international convention UVR is divided into three wave-
length ranges: long-wave UVA (320–400 nm), medium
wave UVB(290–320 nm), and short wave UVC (200–290
nm)18. The energy of each part of the radiation is in-
versely related to the wavelength. UVC, the most ener-
getic, is completely filtered by the ozone layer in the
stratosphere, so that the most active part of UVR which
reaches the earth surface are UVB rays and make ap-
proximately 5% of the UVR reaching the soil. UVB radia-
tions are known to have pleotropic biological effects on
the skin, acute or chronic, causing inflammation, apopto-
sis, local and systemic immunosuppression, and absor-
bed by DNA, it damages and act directly as a mutage-
nic18–21.
UVA rays represent the predominant component of
solar UVR and make up about 95% of UV rays that reach
the earth's surface. Their energy is relatively small; how-
ever, they penetrate deeper into the skin. They cause
quick browning, skin aging, and generating a variety of
reactive oxygen species (ROS) such as hydrogen pero-
xyde, superoxyde, peroxy nitrite, which indirectly dam-
age DNA forming purine oxidative (mainly guanin) pho-
toproducts such as 8-oxo7,8dihydro-2'deoxy-guanosine,
and strand breaks. UVA inducing matrix metallopro-
teinases, via AP-1 and NF- B, increase the agressivity of
skin cancer. So, even if the UVB and UVA differ in their
biological effects and depth of penetration, both radia-
tions can induce DNA damage causing delayed genomic
instability and induce ROS which can be involved in all
the stages of carcinogenesis, and have also immuno-
suppressive properties (see recent reviews)22–25. Intense
acute, intermittent or chronic exposure to UVR of solar
origin or from artificial sources, in spite of the cutaneous
defense and repair mechanisms (melanin synthesized by
melanocytes, stratum corneum, trans-urocanic acid,
DNA repair, antioxidant enzymes such as catalase and
superoxide dismutase, apoptosis) can lead to the develop-
ment of precancerous lesions (actinic keratosis) and dif-
ferent skin tumors NMSC and melanoma7,26.
Epidemiologic studies have assessed the relevance of
UVR exposure in the development of non-melanoma can-
cers: basal cell carcinoma is related to cumulative sun ex-
posure, sunburn in childhood and also to intermittent ex-
posure (on the trunk), while squamous cell carcinoma is
more related to lifelong cumulative exposure. In the case
of melanoma it seems to be associated with intense inter-
mittent UVR exposure, and is located frequently on the
back in males and on the lower legs in females13,26–29.
UVR Induced Mutation in Tumor
Suppressor Genes and in Protooncogenes
Photocarcinogenesis is a complex multistage process
involving mutation of more genes and the transformed
cells escape from immunosurveillance and undergo clo-
nal expansion.
UVB photons are directly absorbed by nuclear DNA of
keratinocytes with transfer energy into biochemical, cau-
sing its damage i.e. mutagenic photoproducts which, if
not repaired before DNA replication, lead to mutation in
cancer relevant genes, partly tumor specific. These genes
are: suppressor genes (whose protein products regulate
DNA damage, apoptosis, cell cycle control), protoonco-
genes (whose physiological function is organ growth and
tissue repair) when activated become oncogenes, and
genes envolved in the regulation of cell cycle30–32. Other
genes regulating the skin pigmentation are also impor-
tant in the development of skin tumors and so the inves-
tigation of photocarcinogenesis represents a good model
of how genetics and environment interact in its patho-
genesis.
The DNA damage can be responded with DNA repair,
cell cycle checkpoint control, apoptosis and only partly
with tolerance (post replication repair or template swit-
ching).
UVB induces damage of DNA particularly on neigh-
boring pyrimidine bases thymine (T) and or cytosine (C)
on the same strand forming a four-membered cyclobu-
tane ring or 6,4 photoproducts. There are C to T transi-
tion or CC to TT double base mutation33–35. These chan-
ges are exclusive on adjacent dypirimidine sites, so they
represent a specific marker of UVR involvement in pho-
tocancerogenesis (fingerprints or signature mutations).
Such fingerprints can be found also in normal sun ex-
posed areas36. Although these are the most common UVR
induced DNA damages, there are also some others: pro-
tein DNA cross-links, single strand breaks, oxidation
damage but they are not specific and can be caused by
various carcinogens. Most of UVR induced DNA damage
is quickly enzymatically corrected by the nucleotide exci-
sion repair (NER) and consist of recognition of the lesion,
unwinding of the DNA helix, demarcation of the lesion,
dual incision and excision of the damaged region and re-
synthesis of the gap, and ligation by DNA polymerase
and ligase37–39. In this repair process among others the
XP proteins have an important role. There are also other
types of repair mechanisms: base excision repair, mis-
match repair, double strand break repair38. Goukassian
and al. have recently demonstrated on human dermal
fibroblasts that after UVR exposure the NER of pho-
toproducts significantly decreases with age from new-
borns to young persons, and to older people. They also
found an age–associated decrease of mRNA level of NER
proteins. This decreased DNA repair mechanism related
to age is likely to increase the incidence of skin cancer in
the elderly40. In NER deficient syndromes such as the
xeroderma pigmentosum, which comprises 8 varieties
from XP-A through XP-G and XP-V, characterized by high
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sensitivity to UV rays, with sunburns, freckling and
sometimes abnormalities of the central nervous system,
the UVR induced damage is not recognized or incorrectly
repaired. In the patients the bases remain permanently
mutated which lead to an early high incidence of precan-
cerous lesions and skin tumors (squamous cell carci-
noma, basal cell carcinoma, melanoma, and other)41,42. The
XPA is the most severe and XPC the most common vari-
ant. Moreover, transgenic mice without these genes have
increased photosensitivity and are prone to develop skin
tumors42.
Photocarcinogenesis implicates the mutation i.e. in-
activation of one or more tumor suppressor genes (anti-
oncogenes) with altered aminoacid sequences in their
coded protein product, deletion or overactivation of some
protooncogenes which become oncogene and the encoded
protein releases the cell from growth restraints. The sup-
pressor gene products in normal cell are inactivated by
binding to other proteins or by phosphorilation, in neo-
plastic cell they are mutated or deleted. Tumor suppres-
sor genes usually are recessive i.e. require the inactiva-
tion or deletion of both alleles15,43,44. Interestingly enough,
such recessive genes can seem dominant, if one allele is
heredited and the other inactivated by some environ-
mental agent (UVR), in agreement with the Knudson s'
»two hits model» theory44,45. Point alterations of the sup-
pressor gene p53, » the guardian of the genome»(firstly
presumed to be an oncogene) are the most frequent mu-
tations in human cancers. It can be activated by numer-
ous form of cell stress: irradiation, hypoxia, chemicals
etc43. UVR induces mutation of p53 gene typically on py-
rimidine sites. Its protein product, a transcriptional fac-
tor and key of cell regulation, is expressed at very low
levels in normal cells, and this – »wild type», cannot be
demonstrated by immunohistochemistry, while the mu-
tant is easily observed. P53 is regulated by human double
minute2 (Hdm2) protein, that bind it inhibiting its
transcriptional activity and is then degraded in the pro-
teosome. p53 is able, after DNA damage, to induce tran-
scription of p21 a cyclin kinase inhibitor which prolong
or arrest the cell cycle in the G1 phase allowing the re-
pair of DNA, enhance apoptosis (programmed cell death)
of mutated cells upregulating the expression of proapo-
toptic genes (Bax, Fas), inhibit angiogenesis, and also
take part in the DNA repair46–48. Experiments in UV ir-
radiated transgenic mice P53-/- have shown a reduction
in apoptosis. So, the deletion or mutation of p53 gene or
inactivation of the protein product by Hmd2 can lead to
the development of tumors. Jiang and al. have demon-
strated in knock out mice that UV irradiation induces
sooner and more skin tumors in p53 -/- and P53 +/-ani-
mals, and even ocular melanoma than in controls49. Mu-
tation of p53 genes have been detected in approximately
50% of all human tumors; in basal cell carcinoma it is
mutated in about 30–50% of the cases, and in a greater
percentage in squamous cell cancer. Our investigation
also demonstrated an increase of p53 in some prolife-
rative dermatoses and skin tumors15. Recent studies
have shown that in basal cell carcinoma the codon 177
have been mutated, whilst in squamous cell carcinoma
the same occurred on codon 27848. In skin carcinomas
p53 is an early mutation, whilst in melanoma it is un-
common and occur later. Experiments in UV irradiated
knock out Gadd 45a mice demonstrated the importance
of this protein and p53 in inducing apoptosis50.
The patched gene PTCH., firstly discovered in the
fruit fly (Drosophyla melanogaster) where it is involved
in embryonic development, later in humans (9q22.3
chromosome), which germline mutation underlies the
nevoid basal cell carcinoma syndrome (Gorlin syndro-
me), characterized by early development of numerous
basal cell carcinomas, skeletal abnormalities, meningio-
mas, pamoplantar pits51. This gene is also mutaded in
30–40% of sporadic cases of basal cell carcinoma52,53. It
also presents C-T and CC-TT transitions characteristic
for UV induced damage. PTCH is also a suppressor gene
and if the mutation is not corrected, the product, a
transmembranous protein, cannot inhibit the activation
of another transmembranous protein, the smoothened
(SMO), and consequently the hedgehog signaling path-
way with activation of the gli2 trancription factors in the
nucleus which upregulates antiapoptotigc genes (bax). In
transgenic mouse strains, it has been demonstrated that
mutated or inactivated PTCH cannot control the cell cy-
cle and lead to apoptosis. Naturally, mutations of PTCH
and /or SMO favour the cells' growth, proliferation and
cell survival, and the development of basal cell carcino-
ma54–56. In the development of squamous cell cancer the
sonic-hedgehog signal pathway plays no role, but p53,
which is present even in actinic keratoses.
The activation of a protooncogene is dominant: chan-
ge in one allele has effect and can stimulate growth or
proliferation of the cell. In humans oncogenes are genes
of the ras family, which encode a membrane protein.
Their activation occurs by point mutations in DNA.
Studies with amplification by PCR, have found activated
ras sometimes in basal cell carcinoma, squamous cell car-
cinoma and melanoma57,58.
The development of melanoma commonly is stepwise:
nevus, dysplasia, radial growth phase, vertical growth,
and metastasis. In familiar melanoma patients carry
germ line mutation in the locus cyclin dependent kinase
inhibitor 2A gene (CDKN 2A) on the chromosome 9p21.
It encodes two supressor proteins p16 (inhibitor kinase
4A-INK4A) and p14 or Arf (alternative reading fra-
me)59–61. The p16 function is to inhibit the complexing
ciklin-CDK4 and 6 and consequently the phosphorilation
of pRB, release of E2F which drives the G1 in S phase of
the cell cycle. Sometimes the mutation of this gene has
been found also in sporadic cases of melanoma, some
with C-T transitions62. Experiments in transgenic mice
have shown the inactivation of retinoblastoma/p16 path-
way, which lead to development of melanoma63. The
function of p14 is to sequester the Mdm2, increasing so
the regulatory p53 activity. A recent international study
by Curtin et al. on 126 cases of melanoma has demon-
strated that in mucosal and acral melanomas there is
commonly a loss of the CDKN2A locus64. Another DNA
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mutation found in melanoma, but also in naevi is BRAF,
which is present in approximately 50% of the cases, and
is the most frequently mutated gene in this tumor, espe-
cially on the non sun exposed areas (trunk, legs). It is a
protooncogene that activates the MEK family59. In 25–
50% of non familiar melanoma is inactivated by muta-
tion or deletion the suppressor gene phosphatase and
tensin (PTEN), which is located on chromosome 10q and
encodes a phosphatase. Mutation of BRAF and PTEN oc-
cur frequently together59. In recent years, there has been
much concern for humans regarding solar or artificial
UVA in the induction of melanoma65.
Recent studies suggested that telomerase is highly ex-
pressed in more than 85% of cancer cells, including mela-
noma, but not in the normal somatic cells 66. Telomerase
is a ribonucleoprotein that is responsible for maintaining
telomeres length on the end of the chromosomes66–67.
The role of telomere is to protect chromosomes from deg-
radation and from aberrant recombination during repli-
cation prolonging the life span of the cell. This enzyme is
mainly repressed in human cells, resulting in progressive
loss of telomeres and shortening of the chromosome with
successive cell divisions. Finally, chromosomes reach a
critical length at which cell division ceases, senescence
begins, and the cell ultimately undergoes apoptosis or
cell death. It has been suggested that telomerase plays a
role in anti-tumor immunity in cancer patients leading to
insufficient host reaction to tumor and its progression68.
Telomerase reverse transcriptase has been shown to
induce CTL response direct against hTERT-positive tu-
mor cells resulting in cell death. Since human T cells ex-
press hTERT upon activation hTERT- specific CTLs could
also mediate killing of activated T cells in an auto-im-
mune manner leading to decrease absolute counts of T
lymphocyte subset and altered lymphocyte homeostasis
in patients with carcinoma. We hypothesized these mech-
anisms to overwhelm apoptosis and initiate proliferation
of melanoma cells69.
Immunosuppression
Thirty years ago Kripke and al. demonstrated in UV
irradiated mice the importance of the immune response
in the carcinogenesis70. She found that UV induced skin
tumors were highly antigenic and rejected when trans-
planted in syngenic mice. However, the transplanted tu-
mors grow progressively if the recipients were exposed to
UVR, and this effect was transferable to other animals
with T lymphocytes71,72. This observation led to the hy-
pothesis that UVR suppressed the immune system both
locally and systemically73,74. So, UVR inducing immuno-
suppression interferes with immunological mechanism
of tumor immunosurveillance73. UV radiations (UVA and
UVB) induce DNA damage, particularly photoproducts
which trigger immunosuppression: alter antigen presen-
tation, depletion of Langerhans cells from the epidermis,
as they are more sensitive to UVR than keratinocytes,
emigration to the regional lymph nodes, and the induc-
tion of regulatory T cells75–78. The result is down-regula-
tion of the cellular immune response such as induction
and elicitation of contact hyper sensitivity, and also an
inhibition of NK cell activity. However, the humoral part
of the immune response is not alterated. These immuno-
depressive effects contribute to cancer development as
the cellular immune mechanisms can destroy tumor cells,
whilst on the other side UVR also induces in keratino-
cytes expression of perforin and granzymes and may
aquire cytotoxicity against other cells79.
Many molecules have been suggested as potential me-
diators of immunosuppression. While some authors be-
lieve the damage of DNA is the primary cause of immu-
nosuppression, others link it to the presence of the
chromophore transuranic acid in the stratum corneum,
which upon UVR exposure isomerizes in the cis configu-
ration that has immunosuppressive action80–82. This was
proved with antibody against cis trans uranic acid83.
Some also think that exposure to UVR promotes forma-
tion of free radicals and membrane lipide peroxydation
which can lead to immunosuppression. Finally, there is
the possibility that upon UV irradiation of keratinocytes,
they release neuropeptids and the alpha melanocyte sti-
mulating hormone ( MSH) which present immunomo-
dulatory effects83,84. This has been demonstrated in mice
to which áMSH was applied topically or intravenously
before the sensitization with contact allergens. The ani-
mals were not sensibilized, but developed specific tole-
rance85. Most of the studies of UVR induced immuno-
suppression have been made in vitro or in rodents using
UVB; there is data that UVA can also induce immuno-
suppression in men and mice, and the application of UVA
sunscreen abrogates this86. Epidemiological data of skin
cancer in patients on immunosuppressive therapy sup-
ports this hypothesis87,88, and experiments in rodents as
well as the use of sunscreen confirmed this.
Patients with psoriasis may be at high risk to develop
precancerous lesions and skin cancer because they use
UVR, PUVA, immunosuppressive drugs, tars in the treat-
ment, but it is of great interest that rarely cancer develop
on the site of psoriatic lesions. It may be that the pres-
ence of TNF , INF in the lesions drive the keratinocytes
to senescence and growth arrest.
In conclusion, we can say that epidemiological, experi-
mental and molecular studies strongly suggest that UVR
induces skin tumors, and photocarcinogenesis and im-
munosuppression are linked and induced by UVR dam-
age of the DNA. The field of photobiology is rapidly en-
larging and further investigation will clarify and lead to a
better understanding of photocarcinogenesis and allow-
ing new treatments of cancer. Today, public information
and photoprotection can help in avoiding skin cancer.
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FOTOCARCINOGENEZA – MOLEKULARNI MEHANIZMI
S A @ E T A K
Uloga sun~anih zraka u nastanku tumora ko`e (fotokarcinogeza) utvr|ena je prije jednog stolje}a. Brojne eksperi-
mentalne studije zadnjih decenija ukazale su na ulogu UV zra~enje u o{te}enju DNA, pojavi mutacija gena {to dovodi do
nastanka malignih tumora ko`e kao {to su bazaliomi, spinaliomi i melanomi. Ovi se tumori ~e{}e razvijaju u osoba
svjetlije puti. Mutacije inducirane UV zrakama nastaju tipi~no na dipirimidinskim dimerima s C-T i CC-TT s duplim
mutacijama. Autori ukratko iznose svoja istra`ivanja p53 supresorskog gena i pretpostavku o ulozi hTERT u kance-
rogenezi. Posebice, ukazuju na ulogu UV zraka na pojavu imunosupresije i njenom zna~enju u nastanku tumora. Pso-
rijati~ni bolesnici su tijekom `ivota izlo`eni u svrhu lije~enja UV zrakama i drugim kancerogenima. Bolje razumijevanje
mehanizama fotokarcinogeneze mo`e koristiti u pronala`enju novih na~ina lije~enja ko`nih tumora.
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